AGA临床实践更新:血清学阴性肠病的评估与管理专家综述
本专家综述基于已发表的队列、病例对照、横断面及病例系列研究,提出血清学阴性但怀疑乳糜泻或其他肠病患者的诊断与管理共识。共给出8条最佳实践建议,涵盖病理复核、血清学检测、膳食评估、药物与旅行史、HLA基因分型、无麸质饮食后内镜复查及布地奈德治疗等。
要点
- 血清学阴性疑诊乳糜泻者应测总IgA,并检测抗组织转谷氨酰胺酶、抗脱酰胺麦胶蛋白肽及肌内膜抗体。
- 总IgA低于检测下限且IgG抗组织转谷氨酰胺酶或抗脱酰胺麦胶蛋白肽阳性者,应考虑选择性IgA缺乏的乳糜泻。
- 血清学阴性但伴绒毛萎缩及遗传风险者,无麸质饮食1-3年后应内镜复查评估绒毛改善以确诊。
核心结论
- 这些最佳实践建议有助于血清学阴性但疑似乳糜泻患者的诊断与管理。
研究设计与样本
- 专家综述,汇总已发表的队列、病例对照和横断面诊断研究以及病例系列和描述性管理研究。
主要发现
- 共提出8条最佳实践建议,涉及病理复核、血清学检测、膳食评估、药物与旅行史、HLA基因分析、无麸质饮食后内镜复查及布地奈德治疗。
关键数值与推荐
- 建议1:与专攻胃肠病的经验丰富病理学家复核组织学发现。
- 建议2:疑诊乳糜泻但血清学阴性者应测总IgA,并检测抗组织转谷氨酰胺酶、抗脱酰胺麦胶蛋白肽及肌内膜抗体(IgA)。
- 建议2:总IgA低于检测下限且IgG抗组织转谷氨酰胺酶或抗脱酰胺麦胶蛋白肽或肌内膜抗体阳性者,应考虑选择性IgA缺乏的乳糜泻而非血清学阴性乳糜泻。
- 建议5:分析人类白细胞抗原基因疾病相关变异,阴性结果可用于排除血清学阴性患者的乳糜泻。
- 建议6:血清学阴性但伴绒毛萎缩和乳糜泻遗传风险因素者,无麸质饮食1-3年后须内镜评估绒毛萎缩改善,基于临床和组织学改善可确诊血清学阴性乳糜泻。
临床怎么用
- 建议3:仔细审查患者膳食,并在血清学检测时采集和分析十二指肠活检以确定麸质暴露和检测准确性。
- 建议4:详细采集用药史(关注血管紧张素II受体阻滞剂如奥美沙坦)和旅行史以识别绒毛萎缩的潜在病因。
- 建议7:血清学阴性患者如发现肠病病因应相应治疗,随访活检可能需要也可能不需要。
- 建议8:持续症状且对无麸质饮食无反应、最终未确定肠病病因者,应使用布地奈德治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DESCRIPTION: Our aim was to provide a consensus statement for the best approaches for diagnosis and management of patients with suspected enteropathy, but negative results from serologic tests for celiac disease (seronegative enteropathy). METHODS: We collected findings from published cohort, case-control, and cross-sectional studies of diagnosis and case series and descriptive studies of management of patients believed to have celiac disease or other enteropathies unrelated to gluten, but negative results from serologic tests. BEST PRACTICE ADVICE 1: Review histologic findings with experienced pathologists who specialize in gastroenterology. BEST PRACTICE ADVICE 2: Serologic tests are essential for an accurate diagnosis of celiac disease. For patients with suspected celiac disease but negative results from serologic tests, total IgA level should be measured; patients should also be tested for anti-tissue transglutaminase, IgA against deamidated gliadin peptide, and endomysial antibody (IgA). Patients with total IgA levels below the lower limit of detection and IgG against tissue transglutaminase or deamidated gliadin peptide, or endomysial antibody, should be considered to have celiac disease with selective IgA deficiency rather than seronegative celiac disease. BEST PRACTICE ADVICE 3: Patients' diets should be carefully reviewed and duodenal biopsies should be collected and analyzed at the time of serologic testing to determine exposure to gluten and accuracy of test results. BEST PRACTICE ADVICE 4: Thorough medication histories should be collected from patients, with attention to angiotensin II receptor blockers, such as olmesartan, along with travel histories to identify potential etiologies of villous atrophy. This will guide additional testing. BEST PRACTICE ADVICE 5: Patients should be analyzed for disease-associated variants in human leukocyte antigen genes; results must be carefully interpreted. Negative results can be used to rule out celiac disease in seronegative patients. BEST PRACTICE ADVICE 6: Patients with suspected celiac disease who are seronegative but have villous atrophy and genetic risk factors for celiac disease must undergo endoscopic evaluation after 1-3 years on a gluten-free diet to evaluate improvements in villous atrophy. A diagnosis of seronegative celiac disease can then be confirmed based on clinical and histologic markers of improvement on the gluten-free diet. BEST PRACTICE ADVICE 7: Seronegative patients with an identified cause for enteropathy should be treated accordingly; a follow-up biopsy might or might not be necessary. BEST PRACTICE ADVICE 8: Patients with persistent signs and symptoms who do not respond to a gluten-free diet, and for whom no etiology of enteropathy is ultimately identified, should be treated with budesonide. CONCLUSIONS: These best practice guidelines will aid in diagnosis and management of patients with suspected celiac disease, but negative results from serologic tests.
引用
- Leonard MM, Lebwohl B, Rubio-Tapia A, et al. AGA Clinical Practice Update on the Evaluation and Management of Seronegative Enteropathies: Expert Review. Gastroenterology. 2020. PMID: 33010252. doi:10.1053/j.gastro.2020.08.061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。